Globally prostatic adenocarcinoma is the second most frequent malignancy after lung cancer in men worldwide, about 1 400 000 cases and causing about 375 000 deaths. Consequently accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide.
Organized screening for prostatic adenocarcinoma is not introduced but middle aged and older men are often recommended screening for prostatic adenocarcinoma by performing blood sampling for analysis of PSA (Prostatic Specific Antigen). Elevated levels of PSA indicate an increased risk for prostatic adenocarcinoma. Males with elevated levels of PSA are recommended to attain a reception in urological surgery to obtain biopsies from the prostatic gland.
Prostatic adenocarcinoma is the most prevalent type of male cancer in Sweden, with over 10 000 new cases diagnosed every year. It constitutes around 30% of all male cancer cases and it occurs mainly in older men. Accordingly, 70% of the tumors are diagnosed in men 70 years of age and older. Over 2 000 males die due to prostatic cancer every year and prostatic adenocarcinoma is the most common cause of death due to a malignant tumor among males in Sweden.